Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenomic considerations for immunosuppressive therapy.

Yoram Yagil1, Chana Yagil

  • 1Department of Nephrology and Hypertension, Faculty of Health Sciences, Ben-Gurion University Barzilai Medical Center Campus, Ashkelon 78306, Israel. labmomed@bgumail.bgu.ac.il

Pharmacogenomics
|April 30, 2003
PubMed
Summary

Pharmacogenomics tailors immunosuppression therapy using an individual's genetic makeup to improve drug efficacy and reduce side effects. While promising, the clinical application of pharmacogenomics in immunosuppression is progressing slowly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut Microbiome Signatures Distinguish Susceptibility from Disease Development in Type 2 Diabetes.

International journal of molecular sciences·2026
Same author

Genetic Terminal Complement Deficiency in Israeli Bedouins With Kidney Failure.

Kidney international reports·2025
Same author

COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry.

Kidney360·2023
Same author

Predisposition to cortical neurodegenerative changes in brains of hypertension prone rats.

Journal of translational medicine·2023
Same author

Dysregulated UPR and ER Stress Related to a Mutation in the <i>Sdf2l1</i> Gene Are Involved in the Pathophysiology of Diet-Induced Diabetes in the Cohen Diabetic Rat.

International journal of molecular sciences·2023
Same author

Mesenchymal Stem Cell-Derived Extracellular Vesicles as Proposed Therapy in a Rat Model of Cerebral Small Vessel Disease.

International journal of molecular sciences·2022

Area of Science:

  • Immunology
  • Pharmacology
  • Genomics

Background:

  • Immunosuppression is crucial for organ transplantation and autoimmune disease treatment.
  • Recent decades have seen advancements in potent immunosuppressive agents.
  • Pharmacogenomics, driven by the human genome project, offers personalized medicine.

Purpose of the Study:

  • To explore the integration of pharmacogenomics into immunosuppression therapy.
  • To define pharmacogenomics of immunosuppression as tailoring drug therapy based on individual genomic profiles.
  • To assess the potential of this approach to optimize treatment outcomes.

Main Methods:

  • This study is primarily a conceptual and review-based exploration.
  • It synthesizes current knowledge on immunosuppression and pharmacogenomics.

Related Experiment Videos

  • It discusses the theoretical framework for applying pharmacogenomics in clinical practice.

    • Main Results:

    • Pharmacogenomics of immunosuppression promises to enhance drug efficacy and minimize toxicity.
    • Matching drugs to individual genomes could improve patient survival and reduce morbidity.
    • The potential benefits include directing clinicians to the most suitable immunosuppressive drugs.

    Conclusions:

    • The integration of pharmacogenomics into immunosuppression holds significant promise for personalized medicine.
    • Despite high expectations, the clinical realization and application of these advancements are currently slow.
    • Further development and implementation are needed to fully harness the potential of pharmacogenomics in immunosuppression.